Saturday, August 1, 2026
Moderna's norovirus vaccine misses Phase 3 interim efficacy bar
Moderna disclosed on July 31, 2026 that the Phase 3 interim analysis of its norovirus vaccine candidate mRNA-1403 (the ~38,000-participant NOVA 301 study) did not meet the statistical threshold for early success. The company is enrolling an additional cohort after case accrual came in slower than expected across two Northern Hemisphere seasons, pushing a definitive efficacy readout to 2027-2028 while it maintains its full-year revenue growth guidance.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- UK MHRA authorizes Moderna XFG Spikevax updateMonday, September 7, 2026
- Moderna prices upsized $2.6 billion convertible notesTuesday, September 1, 2026
- FDA approves Moderna's updated 2026-2027 COVID vaccinesFriday, August 28, 2026
- Moderna to raise $2 billion in convertible senior notesThursday, August 27, 2026